Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection

Urology

Volumn 59, Issue 2, 2002, Pages 261-265

  Tanguay, S ^a,b   Begin L R ^a   Elhilali, M M ^a   Behlouli, H ^a   Karakiewicz, P I ^a   Aprikian, A G ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0036166720     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01497-2     Document Type: Article

References (20)

1. Prostate specific antigen; a decade of discovery-what we have learned and where we are going
2. Rate of change in serum prostate specific-antigen levels as a method for prostate cancer detection
3. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
4. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma
5. Prostate-specific antigen density; a means to distinguishing benign prostatic hypertrophy and prostate cancer
6. Serum PSA in a community-based population of healthy men; establishment of age-specific reference ranges
7. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging
8. Prostate cancer; 5. Diagnostic tolls for early detection
9. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening
10. Use of the percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease; a prospective multicenter trial
11. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate; critical analysis of two different test populations
12. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays
13. PSA, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL
14. Outcome of sextant biopsy according to gland volume
15. Measurement of complexed PSA improves specificity for early detection of prostate cancer
16. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
17. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer
18. Examination of 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy; relationship to transition zone volume
19. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer; results on 4298 cases
20. Clinical evaluation of serum prostate-specific antigen-alpha 1-antichymotrypsin complex values in diagnosis of prostate cancer; a cooperative study